Opendata, web and dolomites

DECISION SIGNED

DECOMPENSATED CIRRHOSIS: IDENTIFICATION OF NEW COMBINATORIAL THERAPIES BASED ON SYSTEMS APPROACHES

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 DECISION project word cloud

Explore the words cloud of the DECISION project. It provides you a very rough idea of what is the project "DECISION" about.

albumin    mainly    precipitating    first    therapies    points    risk    standard    decompensation    death    liver    trial    multiple    refine    receive    day    600    tests    gastrointestinal    acute    absorbable    antibiotics    laxatives    vasoconstrictors    prevent    statins    proton    mechanisms    chronic    worldwide    inhibitors    million    profiling    encephalopathy    standardized    calls    ascites    biological    hepatic    28    combination    betablockers    mortality    interindividual    responsible    patients    data    intravenous    oral    prognostic    treatments    2013    pump    decrease    200    despite    progression    combinatorial    steroids    deaths    presentation    outcome    time    anticoagulants    decision    throughput    decompensated    therapy    events    variability    cirrhosis    treatment    heterogeneity    integrating    omic    agents    underlying    diuretics    pathophysiology    personalization    antiviral    clinical    aclf    hemorrhage    predicting    optimized    animal    samples    models    15   

Project "DECISION" data sheet

The following table provides information about the project.

Coordinator
EUROPEAN FOUNDATION FOR THE STUDY OF CHRONIC LIVER FAILURE (EF-CLIF) 

Organization address
address: TRAVESSERA DE GRACIA 11, 7TH FLOOR
city: BARCELONA
postcode: 8021
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 6˙000˙007 €
 EC max contribution 6˙000˙000 € (100%)
 Programme 1. H2020-EU.3.1.1. (Understanding health, wellbeing and disease)
 Code Call H2020-SC1-2019-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-04-01   to  2025-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EUROPEAN FOUNDATION FOR THE STUDY OF CHRONIC LIVER FAILURE (EF-CLIF) ES (BARCELONA) coordinator 1˙008˙650.00
2    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 620˙500.00
3    Concentris Research Management GmbH DE (Fürstenfeldbruck) participant 488˙500.00
4    ASSISTANCE PUBLIQUE HOPITAUX DE PARIS FR (PARIS) participant 445˙472.00
5    JOHANN WOLFGANG GOETHE-UNIVERSITATFRANKFURT AM MAIN DE (FRANKFURT AM MAIN) participant 404˙222.00
6    FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA ES (BARCELONA) participant 396˙722.00
7    FUNDACION PUBLICA MIGUEL SERVET ES (PAMPLONA) participant 382˙500.00
8    COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES FR (PARIS 15) participant 345˙000.00
9    UNIVERSITAETSKLINIKUM AACHEN DE (AACHEN) participant 300˙874.00
10    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) participant 300˙000.00
11    YH YOUHEALTH AB SE (STOCKHOLM) participant 260˙000.00
12    ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA IT (BOLOGNA) participant 196˙722.00
13    UNIVERSITY COLLEGE LONDON UK (LONDON) participant 130˙879.00
14    INSTITUT CATALA DE LA SALUT ES (BARCELONA) participant 130˙472.00
15    SERVICIO MADRILENO DE SALUD ES (MADRID) participant 130˙472.00
16    UNIVERSITA DEGLI STUDI DI TORINO IT (TORINO) participant 130˙472.00
17    UNIVERSITAT DE BARCELONA ES (BARCELONA) participant 120˙000.00
18    NORDIC BIOSCIENCE A/S DK (HERLEV) participant 66˙043.00
19    EUROPEAN ASSOCIATION FOR THE STUDYOF THE LIVER CH (ZURICH) participant 50˙000.00
20    EUROPEAN LIVER PATIENTS ASSOCIATION BE (BRUXELLES) participant 50˙000.00
21    UNIVERSITA DEGLI STUDI DI PADOVA IT (PADOVA) participant 42˙500.00

Map

 Project objective

In 2013, cirrhosis was responsible for 1.2 million deaths worldwide. This mortality is mainly due to cirrhosis decompensation, i.e. development of ascites, hepatic encephalopathy, and/or gastrointestinal hemorrhage, and its progression to acute-on-chronic liver failure (ACLF). Patients with decompensated cirrhosis receive many treatments such as intravenous and oral absorbable antibiotics, oral non-absorbable antibiotics, albumin, proton-pump inhibitors, laxatives, diuretics, betablockers, vasoconstrictors, statins, anticoagulants, steroids and antiviral agents. Despite these multiple treatments, ACLF or mortality in patients with decompensation of cirrhosis remains high (15% at day 28, 28% at day 90) because of large interindividual variability in precipitating events, in clinical presentation and in response to treatment. This heterogeneity calls for treatment personalization according to underlying mechanisms. The objective of DECISION is to enhance our understanding, at systems level, of the pathophysiology of decompensation of cirrhosis leading to ACLF or death to decrease patients’ mortality at day 28. First, DECISION will improve our knowledge of the pathophysiology of decompensation of cirrhosis by integrating results of high-throughput multi-omic profiling with comprehensive clinical data from 2,200 fully characterized patients (more than 8,600 time points) with available standardized biological samples. Second, we will identify novel combinatorial therapies for patients with decompensation of cirrhosis to prevent death. We will refine these therapies in new and/or optimized animal models and then test the best combination in high risk patients in a phase II clinical trial built in DECISION. Third, we will develop 2 tests: one predicting outcome of patients with decompensation of cirrhosis when treated with standard treatment (prognostic test); and the other identifying patients who will respond to the novel combinatorial therapy (test for response).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DECISION" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DECISION" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.1.)

DC-ren (2020)

Drug combinations for rewriting trajectories of renal pathologies in type II diabetes (DC-ren)

Read More  

BIND (2020)

Brain Involvement iN Dystrophinopathies

Read More  

DECISION (2020)

DECOMPENSATED CIRRHOSIS: IDENTIFICATION OF NEW COMBINATORIAL THERAPIES BASED ON SYSTEMS APPROACHES

Read More